Major Hepatectomy Clinical Trial
Official title:
Segment IV Hypertrophy After Liver Venous Deprivation Compared to Portal Embolization in Patient Before Major Hepatectomy
Verified date | April 2020 |
Source | University Hospital, Montpellier |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
before major hepatectomy, in case of insufisant future liver remanent volume or function,
portal embolization is a routinely used method to enable growth of the future liver remnant.
Recently liver venous deprivation has been described in some pioneer centre. The results are
processing with greater and faster hypertrophy allowing probably less drop out from the
embolization to surgery compared to portal embolization.
In major hepatectomy, and specially in right or extended right hepatectomy the segment IV
plays an important role in the proportion of future liver remnant.
Despite the growing interest in the scientific community for liver venous deprivation many
aspects concerning the liver hypertrophy remains unexplored. In particular the the degree of
hypertrophy of segment IV after liver venous deprivation compared to portal embolization.
Status | Completed |
Enrollment | 40 |
Est. completion date | April 15, 2020 |
Est. primary completion date | April 1, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility |
Inclusion criteria: - patient with liver tumor selected for right hepatectomy with insufficient future liver remnant who have undergoes portal embolization or liver venous deprivation Exclusion criteria: - left / extended left hepatectomy |
Country | Name | City | State |
---|---|---|---|
France | Uh Montpellier | Montpellier |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Montpellier |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | segment IV degree of hypertrophy | segment IV degree of hypertrophy | 1 day | |
Secondary | overall survival | overall Survival : overall survival : is overall survival from date of hepatic surgery until the 01/04/2020 or during 5 years | 5 years | |
Secondary | recurrence free survival | recurrence free Survival : is the the survival without same deasese recurrence from the hepatic surgery date until the 01/04/2020 or during 5 years | 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03762876 -
Evaluation of Trans-Hepatic Flow Changes in Major Hepatectomy
|
||
Recruiting |
NCT02390713 -
Pneumatic Reversible Portal Vein Diameter Modulation After Major Hepatectomy
|
Phase 1/Phase 2 |